Hy-Vee brings telepharmacy to another Iowa community
Hy-Vee is continuing to expand its telepharmacy offerings in Iowa communities. The West Des Moines, Iowa-based company recently opened a new telepharmacy in Manson at a former Medicap pharmacy.
“We are thrilled to provide Hy-Vee pharmacy services and maintain a personal pharmacist connection for residents in Manson through our new telepharmacy location,” Hy-Vee senior vice president and chief health officer Kristin Williams said. “Enhancing health care for our customers is a top priority, and this location will fill prescriptions as well as offer additional health-and-wellness services that Hy-Vee is known for.”
A pharmacist at the Fort Dodge, Iowa, Hy-Vee will verify patient prescriptions for accuracy, dosing and safety, and a certified technician will fill the prescription. Hy-Vee said the telepharmacy uses digital equipment to check fill accuracy. In addition to the pharmacy technician — who worked in the former Medicap pharmacy — the telepharmacy will have a full-time pharmacist onsite 16 hours per month.
The telepharmacy also will offer patient counseling via telephone or iPad. It also will sell a selection of OTC products, the company said.
Amneal launches generic Kenalog-40
Amneal Biosciences is launching its generic of Kenalog-40 (triamcinolone acetonide injectable suspension, 40 mg/ml), with the Food and Drug Administration approved Tuesday. Bridgewater, N.J.-based Amneal said that its generic would be the only one available for the product.
“This important launch demonstrates the depth of our ability to successfully develop and manufacture complex products in our state-of-the-art manufacturing facilities,” Amneal co-CEO and co-chairman Chirag Patel said.
Amneal’s generic will be available in single-dose 1-ml vials, as well as in 5- and 10-ml multi-dose vials. Thr market size for the product was $146 million for the 12 months ended October 2017, according to IQVIA data.
“We are very pleased to launch the only generic injectable of triamcinolone, bringing this affordable medication to patients and healthcare providers,” Amneal Biosciences president Charles Lucarelli said. “We will continue to focus on expanding our portfolio to provide quality generic injectables to our healthcare system.”
FDA approves Sanofi’s Humalog follow-on Admelog
The Food and Drug Administration has given full approval to Sanofi’s Admelog short-acting insulin lispro — a follow-on of Eli Lilly’s Humalog. The product received tentative approval from the FDA earlier this year, and now it is the first short-acting follow-on product to get the FDA’s stamp of approval.
“One of my key policy efforts is increasing competition in the market for prescription drugs and helping facilitate the entry of lower-cost alternatives,” FDA commissioner Scott Gottlieb said. “This is particularly important for drugs like insulin that are taken by millions of Americans every day for a patient’s lifetime to manage a chronic disease. In the coming months, we’ll be taking additional policy steps to help to make sure patients continue to benefit from improved access to lower cost, safe and effective alternatives to brand-name drugs approved through the agency’s abbreviated pathways.”
Admelog was approved under the FDA’s abbreviated approval pathway, in which a manufacturer submits an application that relies partly on the FDA’s finding of safety and efficacy of a reference drug — in this case, Humalog — to support its approval. The product is typically administered before a meal to help manage blood sugar levels after eating in patients with Type 1 diabetes — who typically also require a long-acting insulin, including insulin glargine, insulin degludec or insulin detemir, the FDA said.
"Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes,” Sanofi executive vice president and head of global diabetes and cardiovascular Stefan Oelrich said. “Complementing our existing insulin portfolio, Admelog will offer a more affordable option for those who require control of their blood sugar levels at mealtime. The approval of Admelog is an important milestone for Sanofi in our mission to serve patients living with chronic diseases such as diabetes.”
Sanofi said Admelog would be available in vials and the SoloStar pre-filled pen, which it said is the United States’ most-used disposable insulin pen platform. The FDA approval follows Admelog’s approval by the European Commission in July 2017 as a biosimilar.